Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teprenone - Tokyo Womens Medical College

Next Previous
Drug Profile

Teprenone - Tokyo Womens Medical College

Alternative Names: E 0671; Selbex; Tetraprenylacetone

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tokyo Womens Medical College
  • Developer EA Pharma
  • Class Antiulcers; Cytoprotectives; Diterpenes
  • Mechanism of Action Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gastritis; Peptic ulcer
  • No development reported Cancer

Most Recent Events

  • 24 Mar 2005 Eisai files lawsuits for injunction of unfair competition acts and compensation for damages in Japan against manufacturers and distributors of generic of teprenone (Selbex®)
  • 27 Oct 1998 Launched for Gastritis in Japan (PO)
  • 17 Aug 1998 No-Development-Reported for Cancer in Germany (Unknown route)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top